|
KMID : 0357920060400060427
|
|
Korean Journal of Pathology
2006 Volume.40 No. 6 p.427 ~ p.431
|
|
|
Expression of c-kit and Cell Cycle Regulators in Non-small Cell Lung Carcinoma
|
|
Chang Sun-Hee
Joo Mee
Kim Han-Seong
|
|
|
Abstract
|
|
|
Background: The abnormal expression of c-kit is implicated in the pathogenesis of a variety of solid tumors. The Rb pathway and p53 act as cell cycle regulators. The purpose of this study was to assess the expression of c-kit, Rb, p53, p16 and cyclin D1 and their relationship to clinical and pathological parameters in patients with non-small cell lung carcinomas (NSCLCs).
Methods: Tissue microarrays consisting of 2 mm cores from the corresponding blocks were constructed from 54 NSCLCs. Immunohistochemical staining for c-kit, Rb, p53, p16 and cyclin D1 was performed. C-kit immunostaining was considered positive if ≥10% of tumor cells were immunoreactive along the membrane and/or in cytoplasm. For Rb, p53, p16 and cyclin D1, tumor cells showing a nuclear staining pattern were interpreted as positive.
Results: We found that c-kit was expressed in 13 (24%) cases, Rb was lost in 39 (72%) cases, p53 was expressed in 28 (52%) cases, p16 was lost in 42 (78%) cases and cyclin D1 was expressed in 33 (61%) cases. The c-kit expression was significantly higher in adenocarcinoma (39%) than in squamous cell carcinoma (8%). We did not find any correlation between c-kit, Rb, p53, p16 and cyclin D1 expression and clinicopathological parameters such as: age, tumor size, lymph node involvement, disease stage and distant metastasis. There was a direct correlation between p53 expression and Rb loss.
Conclusions: These results suggest that c-kit may be a useful therapeutic target for patients with c-kit positive tumors, and that the disruption of Rb and p53 pathways may play an important role in the development and progression of NSCLCs.
|
|
|
KEYWORD
|
|
|
Non small cell lung carcinoma, c-kit, Rb, p53, Cell cycle proteins
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|